MashGet

Shares of Human Genome Sciences Inc. soared Monday following news that the firm's experimental lupus drug successfully passed its latest round of testing.

After trading at around $2.50 for much of last week, the stock soared to nearly $11 in the early afternoon. Analysts have predicted that the company's stock could pass $15 if the drug is eventually approved.

The HGS drug, called Benlysta, has one more major round of testing that it must complete successfully if it is to win the approval of the Food and Drug Administration.